高好考,陈根锐,程亮,夏陈海,谢伟炜,王琼,陶凌,李成祥

• 1:空军军医大学第一附属医院心血管内科
• 2:空军军医大学第一附属医院心血管外科

摘要(Abstract)：

目的探讨体外膜肺氧合(ECMO)联合主动脉内球囊反搏(IABP)预防性应用于高危经皮冠状动脉介入治疗(HR-PCI)患者的短期临床疗效。方法选择2018年5–8月10例HRPCI患者,术中应用ECMO联合IABP循环支持。结果 10例患者中男性8例,女性2例,年龄51～84(70.3±11.1)岁,平均左心室射血分数(35.7±10.2)%。10例患者均为严重三支病变,左主干病变7例,其中合并右冠状动脉(RCA)慢性完全闭塞(CTO)病变5例,前降支CTO病变2例;剩余3例中2例为RCA和左前降支(LAD)近/中段CTO病变,1例为RCA CTO病变合并LAD/左回旋支(LCX)严重狭窄。在ECMO联合IABP支持下7例左主干病变中先处理左主干病变6例,1例处理了RAC CTO病变和LAD重度狭窄;剩余3例中2例RCA和LAD近/中段CTO病变均先处理了LAD CTO病变,另1例RCA CTO病变合并LAD/LCX严重病变患者先处理了RCA CTO病变。术中ECMO平均灌注流量(1.80±0.30)L/min,总运转时间(3.4±0.7)h。PCI平均手术时间(2.2±0.5)h。1例PCI术中发生血流动力学崩溃,ECMO灌注流量提高到3.0 L/min维持血流动力学,直到循环正常。术后所有患者ECMO均成功撤机。2例患者IABP穿刺部位血肿,其中1例术后发现假性动脉瘤;1例术后于ICU发生室性心动过速和心室颤动;无ECMO管道机械性问题、下肢缺血和感染并发症发生。结论对不适合行外科血管重建术的HR-PCI术患者,ECMO联合IABP循环支持下行PCI术是可行的。

关键词(KeyWords)： 经皮冠状动脉介入治疗;主动脉内球囊反搏;体外膜肺氧合

Abstract:

Keywords:

基金项目(Foundation): 国家自然科学基金(81570210、81670229)

作者(Author): 高好考,陈根锐,程亮,夏陈海,谢伟炜,王琼,陶凌,李成祥

参考文献(References)：

• [1] Sukiennik A, Kasprzak M, Mazurek W, et al. High-risk percutaneous coronary intervention with Impella CP hemodynamic support. A case series and method presentation. Postepy Kardiol Interwencyjnej,2017,13(1):67-71.
• [2] Vetrovec GW. Hemodynamic support devices for shock and highrisk PCI:when and which one. Curr Cardiol Rep,2017,19(10):100.
• [3] Windecker S, Kolh P, Alfonso F, et al. 2014 ESC/EACTS Guidelines on myocardial revascularization:the task force on myocardial revascularization of the European Society of Cardiology(ESC)and the European Association for Cardio-Thoracic Surgery(EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions(EAPCI).Eur Heart J,2014,35(37):2541-2619.
• [4] Rihal C, Naidu S, Givertz M, et al. 2015 SCAI/ACC/HFSA/STS clinical expert consensus statement on the use of percutaneous mechanical circulatory support devices in cardiovas-cular care:endorsed by the American Heart Assocation, the Cardiological Society of India, and Sociedad Latino Americana De Cardiologia Intervention; affirmation of value by the Canadian association of Interventional Cardiology-Association Canadienne De Cardiologie D'intervention. J Am Coll Cardiol, 2015, 65(19):2140-2141.
• [5] Myat A, Patel N, Tehran S, et al. Percutaneous circulatory assist devices for high-risk coronary intervention. JACC Cardiovasc Interv, 2015, 8(2):229-244.
• [6] O’gara PT, Kushner FG, Ascheim DD, et al.2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction:a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. J Am Coll Cardiol, 2013, 61(4):e78-e140.
• [7] Chen S, Yin Y, Ling Z, et al. Short and long term effect of adjunctive intra-aortic balloon pump use for patients undergoing high risk reperfusion therapy:a Meta-analysis of 10 international randomized trials. Heart, 2014, 100(4):303-310.
• [8] Tomasello SD, Boukhris M, Ganyukov V, et al. Outcome of extracorporeal membrane oxygenation support for complex highrisk elective percutaneous coronary inter-ventions:a single-center experience. Heart Lung, 2015, 44(4):309-313.
• [9] Guenther S, Theiss HD, Fischer M, et al. Percutaneous extracorporeal life support for patients in therapy re-fractory cardiogenic shock:initial results of an interdisciplinary team. Interact Cardiovasc Thorac Surg, 2014, 18(3):283-291.
• [10] Madershahian N, Wippermann J, Liakopoulos O, et al. The acute effect of IABP-induced pulsatility on coronary vascular resistance and graft flow in critical ill patients during ECMO. J Cardiovasc Surg(Torino), 2011, 52(3):411-418.
• [11] Gass A, Palaniswamy C, Aronow WS, et al. Peripheral venoarterial extracorporeal membrane oxygenation in combination with intra-aorticballoon counterpulsation in patients with cardiovascular compromise.Cardiology, 2014, 129(3):137-143.
• [12] Basra SS, Loyalka P, Kar B. Current status of percu-taneous ventricular assist devices for cardiogenic shock. Curr Opin Cardiol,2011, 26(6):548-554.
• [13] Leung WH. Coronary and circulatory support strate-gies for percutaneous transluminal coronary angio-plasty in high-risk patients.Am Heart J,1993,125(6):1727-1738.
• [14] Lincoff AM, Popma JJ, Ellis SG, et al. Percutaneous support devices for high risk or complicated coronary angioplasty. J Am Coll Cardiol, 1991, 17(3):770-780.
• [15] Ho KW, D?avík V. Haemodynamic support devices for complex and high-risk percutaneous coronary intervention. Interv Cardiol, 2011,6(1):17-24.
• [16] Naidu SS. Novel percutaneous cardiac assist devices:the science of and indications for hemodynamic support. Circulation, 2011, 123(5):533-543.
• [17] Harmon L, Boccalandro F. Cardiogenic shock secondary to severe acute ischemic mitral regurgitation managed with an Impella 2.5percutaneous left ventricular assist device. Catheter Cardiovasc Interv, 2012, 79(7):1129-1134.
• [18] Froesch P, Martinelli M, Meier P, et al. Clinical use of temporary percutaneous left ventricular assist devices. Catheter Cardiovasc Interv, 2011, 78(2):304-313.
• [19] Dangas GD, Kini AS, Sharma SK, et al. Impact of hemodynamic support with Impella 2.5 versus intra-aortic balloon pump on prognostically important clinical outcomes in patients undergoing high-risk percutaneouscoronary intervention(from the PROTECT II randomized trial). Am J Cardiol, 2014, 113(2):222-228.
• [20] Vranckx P, Meliga E, De Jaegere PP, et al. The TandemHeart,percutaneous transseptal left ventricular assist device:a safeguard in high-risk percutaneous coronary interventions. The six-year Rotterdam experience. EuroIntervention, 2008, 4(3):331-337.
• [21] Vranckx P, Schultz CJ, Valgimigli M, et al. Assisted circulation using the TandemHeart during very high-risk PCI of the unprotected left main coronary artery in patients declined for CABG. Catheter Cardiovasc Interv, 2009, 74(2):302-310.
• [22] Taub JO, L'Hommedieu BD, Raithel SC, et al. Extracorporeal membrane oxygenation for percutaneous coronary angioplasty in hig h riskpatients. ASAIO Trans, 1989, 35(3):664-666.
• [23] Vainer J, van Ommen V, Maessen J, et al. Elective highrisk percutaneous coronary interventions supported by extracorporeal life support. Am J Cardiol, 2007, 99(6):771-773.
• [24]潘绪,李田昌,汤楚中,等.体外膜肺氧合用于危重经皮冠状动脉介入治疗.中国介入心脏病学杂志,2013,21(6):346-349.
• [25] Chamogeorgakis T, Rafael A, Shafii AE, et al. Which is better:a miniaturized percutaneous ventricular assist device or extracorporeal membrane oxygenation for patients with cardiogenic shock? ASAIO J, 2013,59(6):607-611.
• [26]中华医学会心血管病学分会介入心脏病学组,中国医师协会心血管内科医师分会血栓防治专业委员会,中华心血管病杂志编辑委员会.中国经皮冠状动脉介入治疗指南(2016).中华心血管病杂志,2016,44(5):382-400.